ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1615

Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Abstract Number: 1616

Drug Use and Pregnancy Outcomes in Pregnant Women with Systemic Vasculitis: A Nation Wide Cohort Study
Abstract Number: 1617

Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging: Early Diagnostics in Patients Suspected of Giant Cell Arteritis
Abstract Number: 1618

Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Monitoring of Giant Cell Arteritis
Abstract Number: 1619

Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities
Abstract Number: 1620

Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Abstract Number: 1621

Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)
Abstract Number: 1622

TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Abstract Number: 1623

Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Abstract Number: 1624

Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis
Abstract Number: 1625

Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans
Abstract Number: 1626

Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome
Abstract Number: 1627

BAFF-var Is a New Predisposing Factor for Primary Sjögren’s Syndrome (pSS) and Impacts Disease Activity
Abstract Number: 1628

The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome
Abstract Number: 1629

AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].